The past decade has seen exciting progress in the management of lupus nephritis, a manifestation of systemic lupus erythematosus that accounts for its major morbidity and mortality. The American College of Rheumatology has issued new guidelines for screening and treatment of lupus nephritis, based on expert recommendations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hahn, B. H. et al. American College of Rheumatology guidelines for screening, treatament, and management of lupus nephritis. Arthritis Care Res. 64, 797–808 (2012).
Chan, T. M. et al. Long-term study of mycophenolate mofetil as continuous induction-maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 16, 1076–1084 (2005).
Houssiau, F. A. et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis. 69, 2083–2089 (2010).
Dooley, M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886–1895 (2011).
Ginzler, E. M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219–2228 (2005).
Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103–1112 (2009).
Rovin, B. H. et al. Induction therapy in severe lupus nephritis: should MMF be considered the drug of choice? Clin. J. Am. Soc. Nephrol. (in press).
Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215–1226 (2012).
Condon, M. B. et al. Treatment of class IV lupus nephritis with rituximab and mycophenolate mofetil (MMF) with no oral steroids is effective and safe (abstract). J. Am. Soc. Nephrol. 21 (Suppl.) 625A–626A (2010).
Dooley, M. A. Effect of belimumab treatment on renal outcomes: results from phase 3 belimumab clinical trials in patients with systemic lupus erythematosus (abstract). Arthritis Rheum. 63 (Suppl. S10), S963–S964 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Ginzler, E. Management of lupus nephritis—new guidelines revealed. Nat Rev Rheumatol 8, 565–566 (2012). https://doi.org/10.1038/nrrheum.2012.131
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.131
This article is cited by
-
Transatlantic management recommendations compared
Nature Reviews Rheumatology (2012)
